Rocket Pharmaceuticals ($RCKT) Gene Therapy Trial Failure, Concealed Protocol Changes, and Stock Crash Case

• $RCKT investors filed a claim against Rocket Pharmaceuticals for hiding fatal risks in its gene therapy trial and misleading shareholders about the safety of its Danon disease program.

• After the FDA halted Rocket’s Phase 2 trial due to a patient death from capillary leak syndrome—tied to an undisclosed protocol change—$RCKT dropped 37% on May 27, 2025.

• $RCKT investors can join this case to be notified about potential recovery.

Case Details:

Between February 27, 2025 and May 26, 2025, Rocket assured investors its RP-A501 trial for Danon disease was progressing safely, with favorable safety data and clear timelines. The company emphasized its long-term safety record and efficacy results while continuing enrollment in its pivotal Phase 2 trial.

However, Rocket had secretly altered the clinical protocol by adding a novel C3 inhibitor to the immune suppression regimen. This change was implemented months before a patient died during the trial—yet was never disclosed to investors. The patient developed capillary leak syndrome and later died from an acute systemic infection. A second patient also developed similar symptoms.

On May 27, 2025, Rocket revealed the death and disclosed that the FDA had placed the trial on hold. Analysts expressed concern over the lack of transparency and the material impact on Rocket’s lead program. J.P. Morgan and Cantor sharply downgraded the stock, citing a likely insurmountable setback.

Based on these events, $RCKT investors filed a claim against Rocket Pharmaceuticals, accusing the company of the following:

• Misleading investors about the safety and progress of its RP-A501 trial.

• Failing to disclose serious protocol changes and the associated patient risk.

• Concealing the true status of the trial until after a fatal adverse event occurred.

Investors allege Rocket inflated its valuation and misrepresented clinical safety to preserve investor confidence.